1. Home
  2. AGIO vs DV Comparison

AGIO vs DV Comparison

Compare AGIO & DV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • DV
  • Stock Information
  • Founded
  • AGIO 2007
  • DV 2008
  • Country
  • AGIO United States
  • DV United States
  • Employees
  • AGIO N/A
  • DV N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • DV Computer Software: Prepackaged Software
  • Sector
  • AGIO Health Care
  • DV Technology
  • Exchange
  • AGIO Nasdaq
  • DV Nasdaq
  • Market Cap
  • AGIO 2.4B
  • DV 2.5B
  • IPO Year
  • AGIO 2013
  • DV 2021
  • Fundamental
  • Price
  • AGIO $40.72
  • DV $11.29
  • Analyst Decision
  • AGIO Strong Buy
  • DV Buy
  • Analyst Count
  • AGIO 5
  • DV 19
  • Target Price
  • AGIO $57.25
  • DV $19.18
  • AVG Volume (30 Days)
  • AGIO 577.5K
  • DV 4.5M
  • Earning Date
  • AGIO 10-30-2025
  • DV 11-05-2025
  • Dividend Yield
  • AGIO N/A
  • DV N/A
  • EPS Growth
  • AGIO N/A
  • DV N/A
  • EPS
  • AGIO 11.13
  • DV 0.31
  • Revenue
  • AGIO $40,875,000.00
  • DV $714,259,000.00
  • Revenue This Year
  • AGIO $23.76
  • DV $18.59
  • Revenue Next Year
  • AGIO $148.23
  • DV $11.94
  • P/E Ratio
  • AGIO $3.67
  • DV $35.85
  • Revenue Growth
  • AGIO 30.57
  • DV 16.54
  • 52 Week Low
  • AGIO $23.42
  • DV $10.99
  • 52 Week High
  • AGIO $62.58
  • DV $23.11
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 63.66
  • DV 23.34
  • Support Level
  • AGIO $39.32
  • DV $10.99
  • Resistance Level
  • AGIO $41.42
  • DV $11.43
  • Average True Range (ATR)
  • AGIO 1.34
  • DV 0.44
  • MACD
  • AGIO 0.34
  • DV -0.05
  • Stochastic Oscillator
  • AGIO 87.58
  • DV 15.69

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About DV DoubleVerify Holdings Inc.

DoubleVerify Holdings Inc is a digital media measurement and analytics software platform. Its solutions provide advertisers with unbiased data analytics that enable them to increase the effectiveness, quality, and return on their digital advertising investments. Its DV Authentic Ad, a proprietary metric of digital media quality, measures whether a digital ad was delivered in a brand-suitable environment, fully viewable, by a real person, and in the intended geography. The company's software interface, DV Pinnacle, delivers these metrics to customers in real time, allowing them to access critical performance data on their digital transactions. Geographically, the company operates in the United States and also has a presence in Germany, Singapore, France, Canada, Japan, and other countries.

Share on Social Networks: